Department of Biotechnology, Delhi Technological University, New Delhi, 110042, India; Department of Bioengineering, University of California San Diego, La Jolla, CA 92093, USA.
Department of Biotechnology, Delhi Technological University, New Delhi, 110042, India.
Microb Pathog. 2023 Nov;184:106356. doi: 10.1016/j.micpath.2023.106356. Epub 2023 Sep 24.
The world has witnessed the cruelty of COVID-19 disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The association of COVID-19 with other secondary and bacterial co-infections has tremendously contributed to lung infections. An increased probability of having a secondary lung infection was observed among the post-COVID patients. The treatment of antibiotics has ameliorated the mortality rate. However, the stewardship of antibiotic treatment was linked to increased organ failure. Therefore, the paper discusses the interactions between the virus and host through the ACE2 receptors that contribute to COVID-19 development. Furthermore, the paper provides an invaluable compendium history of SARS-CoV-2 genomic composition. It revolves around most classes of antibiotics used to treat COVID-19 disease and post-COVID lung infections with the complete mechanism. This binds with the exertion of the antibiotics for bacterial infection associated with COVID-19 patients and how beneficial and effective responses have been recorded for the treatment. The application of nanotechnology and possible approaches of nanomedicines is also discussed to its potential usage.
世界已经目睹了由严重急性呼吸系统综合征冠状病毒 2（SARS-CoV-2）引起的 COVID-19 疾病的残酷性。COVID-19 与其他继发性和细菌性合并感染极大地导致了肺部感染。在 COVID-19 后患者中观察到继发性肺部感染的概率增加。抗生素治疗改善了死亡率。然而，抗生素治疗的管理与器官衰竭的增加有关。因此，本文通过 ACE2 受体讨论了病毒和宿主之间的相互作用，这些受体有助于 COVID-19 的发展。此外，本文还提供了 SARS-CoV-2 基因组组成的宝贵汇编历史。它围绕着用于治疗 COVID-19 疾病和 COVID-19 后肺部感染的大多数类别的抗生素展开，包括完整的机制。这与 COVID-19 患者相关的细菌感染中抗生素的使用以及针对治疗记录的有益和有效反应有关。还讨论了纳米技术的应用和纳米药物的可能方法及其潜在用途。
